生物标志物驱动的肿瘤精准治疗新征程

Novel precision therapy for tumor driven by biomarkers

癌症发病率在全球范围内仍然呈上升趋势,中国的癌症负担更为沉重,癌症的防治任重道远。肿瘤标志性特征的演变体现了肿瘤的研究历程,为其预防和治疗提供方向。随着对肿瘤发生发展机制的了解和研究的深入,肿瘤的治疗理念和治疗模式也在不断更新,从手术、放疗、化疗等传统的治疗手段逐步向微观、精准的方向发展。免疫治疗带来新的治疗变革,成为重要的肿瘤治疗手段。以微卫星高度不稳定/错配修复缺陷(microsatellite instability-high/mismatch repair deficiency,MSI-H/dMMR)为代表的生物标志物所定义的抗肿瘤疗法获批首个不限组织来源的适应证,开启了肿瘤精准治疗的新征程。期待未来开发更优的防治策略,为肿瘤患者带来更长的生存时间,更好的生活质量。

The incidence of cancer continues to rise worldwide,and the burden of cancer in China is particularly heavy.The journey towards cancer prevention and treatment still has a long way to go.The evolution of the hallmark features is reflected in the research history of tumors,providing direction for their prevention and treatment.With an in-depth understanding of and continued research into the mechanisms underlying tumor occurrence and development,the concepts and models of tumor treatment are constantly being updated,evolving from traditional methods such as surgery,radiotherapy,and chemotherapy towards microscopic and precise approaches gradually.Moreover,immunotherapy has revolutionized the treatment of cancer and become an important means of cancer therapy.Antitumor therapy defined by specific biomarkers regardless of tumor type,represented by microsatellite instability-high/mismatch repair deficiency(MSIH/dMMR),opens up new avenues for precise and tailored cancer treatments.The novel methods are anticipated to pave the way towards developing better prevention and treatment strategies in the future,ultimately leading to longer survival time and better quality of life for patients with cancer.